Archive for the ‘Policy’ Category

AdvaMed Statement on House Reconciliation Legislation

March 7, 2017

FOR IMMEDIATE RELEASE                                                                                                                   March 7, 2017

 

AdvaMed Statement on House Reconciliation Legislation

 

WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker after introduction of reconciliation legislation in the U.S. House of Representatives:

 

“AdvaMed commends the House Ways and Means Committee for moving forward with legislation that will permanently repeal the medical device excise tax. Bipartisan majorities in both the House and Senate are on record in support of repeal of this onerous tax, which has been associated with a significant loss of American jobs. Recent data from the U.S. Commerce Department showed that the medical technology industry experienced a decline of nearly 29,000 U.S. jobs while the tax was in effect. Conversely, an analysis by the American Action Forum demonstrated that permanent repeal of the tax could result in excess of 53,000 additional industry jobs, compared to what would occur if the tax remains in effect. Repealing the tax will provide medical technology innovators with the long-term certainty necessary to support future job growth and sustainable, cutting-edge R&D that will ultimately lead to the next generation of breakthroughs in patient care and treatment. We urge the House and Senate to act expeditiously to pass this important legislation.”

 

# # #

 

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.

 

 

 

Drug Cost Facts: Your comprehensive guide to the drug cost ecosystem

March 6, 2017

March 3, 2017

BIO Logo Horizontal RGB

The Biotechnology Innovation Organization (BIO) today launched DrugCostFacts.org, a new interactive web tool designed to help healthcare stakeholders gain a better understanding of the true facts surrounding drug costs, spending and value.

 

The site features a series of commonly asked questions—ranging from “Why are some drugs expensive?” to “What role do PBMs, insurance companies and wholesalers play in determining what patients pay for their drugs?”—and then answers these questions using infographics, videos and interactive tools. The site also has additional research and reading materials for those who want to dive deeper into these issues. The tool is mobile responsive, allowing users to access information on their phones and tablets.

 

The goal of the site is to provide information—drawn from independent studies, news articles and outside research—that policymakers, the media and the public can rely on when writing or engaging in discussions about issues relating to drug costs and spending. The site also features a “Follow the Debate” section, where users can get more information on topics ranging from drug importation to government negotiations in Medicare that are making headlines and that are part of the current policy and public debate.

 

Below are highlights of some of the elements of the site:

 

(Note: The interactive tools were developed based on publically-available data and each tool includes an explanation of how the calculations were determined.)

 

Understanding Your Drug Costs: Follow the Pill

 

Understanding Your Drug Costs: Follow the Pill is designed to give users a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. The whiteboard video begins with a typical transaction at your local pharmacy. It then traces that purchase back through a series of complex transactions that occur throughout the pharmaceutical distribution and insurance chain. The video breaks down the differences between the list price and the net price of a medicine, explains how the various actors (e.g., pharmacy benefit managers (PBMs), wholesalers, insurance companies, etc.) in the health care ecosystem operate to deliver medicines to patients and at what cost, and demonstrates why it is that a biopharmaceutical company has very little power to determine what a patient ultimately pays for his or her medicine.

Insurance Calculator

The Insurance Calculator is an interactive tool that allows you to explore how changes on the front end of insurance benefit design (e.g., to your deductible or required cost-sharing for drugs) ultimately impact what you pay each month for premiums and other out-of-pocket costs.

 

The calculator allows you to get a better understanding of how insurance design impacts patient out-of-pocket costs. The tool starts you off with two pre-set plans (i.e., an Affordable Care Act Silver Family Plan and a Large Corporate Individual Plan) to give you examples of what common deductible and co-payment amounts can be. Once you gain more familiarity with how to use the tool, choose the “customize” option to explore all of the various elements of a plan benefit. Users are encouraged to experiment with the different parameters, keeping a close eye on “Total Monthly Out-Of-Pocket Costs” on the left-hand side to see just what elements of your insurance plan’s structure impact the costs you bear the most.

 

For example, increasing deductibles may not have as much of an impact on your premiums as you may think. In addition, you’ll see that increasing brand drug cost-sharing by patients does little to lower your premium, but has a major impact on your out-of-pocket costs.

 

Like the tool discussed below, this insurance calculator is not meant to provide exact data on your individual plan or an individual patient’s costs—instead, it uses real-world data to map the relationship between insurance benefit design of a plan like yours and out-of-pocket costs to demonstrate the effect that one has on the other.

 

How Much Does the Cost of an Innovative New Drug Impact Overall Health Care Costs?

 

When an innovative new medicine becomes available on the market, insurance companies often raise concerns that covering the drug will put upward pressure on health care costs. To take a deeper look at this issue, BIO developed an interactive tool that simulates the impact of adding a new innovative drug on average health care costs across a hypothetical insurance market. The site allows you to enter the monthly cost of a new medicine and the number of people who would take the drug to determine what an approximate monthly impact would be on health care costs if the cost were distributed equally nationwide. What you will see is that, even in the case of more expensive drugs, the incremental cost across all insured individuals is modest. This is important information to know when the alternative is restricting access to these new medicines, and in turn, restricting the potential benefits they would have for patients.

 

Here are a few scenarios you can try: Take your typical statin, which would cost about $10 per month. The population taking this drug would be about two million people. As the calculator shows, the incremental impact on each individual’s health care costs would be about $0.11 a month. Remember, these numbers are not meant to be exact for any particular plan or individual, but instead to demonstrate the magnitude of the impact of covering medicines on health care costs.

 

Another scenario would be a novel therapy costing $1,000 per month and taken by 100,000 patients, which could be the case for a new medicine that treats a certain type of cancer or a specific form of cardiovascular disease. Ensuring coverage of this drug for all patients that need it would have a monthly impact of just $0.56. Or, for example, if a more expensive rare disease drug cost $25,000 per month, and is utilized by 2,000 patients, the monthly impact would be $0.28.

 

Try it out yourself to see how both common and rarer medicines impact the insurance system. We think you’ll quickly see how easy it is for insurance plans to provide robust drug coverage for patients who need new medicines without fear of significant cost increases.

 

Additional Tools

 

In addition to these tools, the site includes an animated video that follows a molecule from the lab through the drug development process, and it features a range of downloadable infographics on topics – from where new drugs are being developed to the role of private sector R&D in drug development.

 

With this resource, BIO has created a one-stop shop for factual information and answers to some of the most hotly debated questions regarding the role of drugs in our nation’s health care system.

January 2017 -Understanding 21st Century Cures for Drugs and Devices

February 1, 2017

This month we’ll discuss the 21st Century Cures Act – a $6.3 billion, nearly 1,000-page, comprehensive legislation package that passed the U.S. House and Senate in late December 2016. 21st Century Cures overhauls the way drugs and devices will be coming to market; the legislation offers grant funding to states to help fight the opioid epidemic and addresses mental health laws and resources. It also places a big emphasis on research funding – especially for cancer and neurodegenerative diseases – and patient rights. All of these factors are expected to change the research-to-commercialization pathway. Please join us as we learn more about the act and its impact on patients, regulators, and large and small companies.

Presenters:

Jeanne Haggerty, Senior Vice President, Federal Government Relations
BIO

Lynn Tyler, Partner
Barnes & Thornburg LLP

Moderator:

Kristin Jones
Indiana Health Industry Forum

The Indiana Health Industry Forum and Barnes & Thornburg LLP partner to present a monthly seminar series on critical issues in life science. Each month, at lunch, a policymaker or a panel in the field of life science will be available to answer questions concerning the major challenges and opportunities in the life science industry. We hope you will join us.

For more information on upcoming programs, please visit www.ihif.org/pages/lifescience

Follow us on Twitter @IHIF1 #LifeScienceLunch @BTLawNews

2015 Advocacy Efforts

November 30, 2016

 

October 2015

Moderated afternoon session of Rep. Susan W. Brooks, “Connecting Classrooms and Careers” program.

September 2015

Signed on to a joint letter to the President urging him to focus on ag biotech issues in his upcoming meetings with President Xi Jinping of China.

August 2015

Participated with IMDMC in Legislative Roundtable, Indianapolis

July 2015

Participated in Hoosiers Work for Health/We Work for Health PhRMA Partnership Fly-In to Washington D.C.

June 2015

Requested Indiana Congressional Delegation to sign-on to bi-partisan letter encouraging fair and balanced patent reform consideration in HR 9.

Met with Rep. Susan W. Brooks at BIO Convention in Philadelphia, provided tour of Indiana booth in the conference exhibit hall

May 2015

Awarded Rep. Susan W. Brooks IHIF’s Legislator of the Year Award for outstanding service to Indiana’s health science sector

Signed on to joint-association letter supporting H.R. 1078, the FDA Safety Over Sequestration (SOS) Act

Participated in Hoosiers Work for Health Award to Rep. Susan W. Brooks

Signed on to Healthcare Leadership Forum letter to repeal IPAB

April 2015

Participated in the BIO Fly-In to Washington, D.C. – met with nine of Indiana’s eleven offices.

March 2015

Signed on to the Declaration Supporting Incentives for Medical Innovation in Trade Agreements organized by the Global Colon Cancer Association and the Information Technology and Innovation Foundation

February 2015

Indiana Expanding Exports and Creating Jobs – Fact Sheet with information on TTIP and TPA impacts on state.

Signed on to National Osteoporosis Foundation letter to Congress supporting Medicare Part D.

January 2015

IHF signed on to a letter to the Administration emphasizing the importance of strong IP and data protections for medicines.  Letter was initiated by the Global Colon Cancer Association and the Information Technology and Innovation Foundation.

IHIF co-hosted our 4th Annual Legislative Breakfast Briefing (agenda) on January 28th.  Co-Hosts include IMDMC and Hoosiers Work for Health/PhRMA

IHIF shared concerns over Senator Elizabeth Warren’s “Medical Innovation Act”.

IHIF provided informational testimony on HB 1065 – Use of investigational drugs, biologics, and devices.  Also expressed concern over SB 66.

IHIF signs on to letter encouraging US legislators to proceed with caution when considering making changes to patent legislation

IHIF signs on to letter to US legislators highlighting the success of Medicare Part D and urging Congress to reject any proposals that would undermine the current program’s success in holding down premiums and taxpayer costs, while still producing high satisfaction rates among enrollees.

2016 Advocacy Efforts

November 30, 2016

Recent Activities

October 2016

Signed on to letter  sponsored by the Healthcare Leadership Council in support of repeal of IPAB.

August 2016

Signed on to letter supporting intellectual property protections in current UN negotiations.

Signed on to BIO letter to SEC supporting re-examination of the definition of ‘Smaller Reporting Companies”.

June 2016

IHIF supports HWFH and opposition to Medicare Part B Demo

May 2016 

IHIF joins BIO and other state bioscience groups in supporting the Fostering Innovation Act – allowing growing bioscience companies to focus on R&D.  Read BIO’s statement on passage of the Act here

IHIF announces Legislators of the Year at 2016 Annual Meeting – Honoring Rep. Larry Bucshon, M.D. and Senator Patricia Miller

April 2016

IHIF attends BIO Fly-In to meet with entire Indiana federal delegation in Washington, D.C. – continuing focus on Medicare Part B reimbursement changes.

March 2016

Provided Letter of Support for HB 3320 – A Bill to Establish a Smart Card Pilot Program Under Medicare

Participated in Lilly 2016 Vendor Conference

Signed on to letter opposing CMS proposed changes to Medicare Part B

January 2016

IHIF testified in favor of HB 1176 – creating a Diabetes Incidence Study and Action Plan through IDOH.  The bill was held and DOH was requested to provide a study update to stakeholders within six months.

IHIF Legislative Breakfast featuring remarks by Rep. Ed Clere and Lt. Governor Sue Ellspermann.

Activity Archive

 

IHIF is a Proud Partner in National Health IT Week

August 21, 2016

This September, IHIF — as a partner in the advancement of health information technology to help improve healthcare —is a Proud Partner in National Health IT Week.  National Health IT Week is the premier event offering all healthcare stakeholders an opportunity to unite under one banner, expressing the benefits that health information technology (IT) brings to U.S. healthcare. “The Value of Health IT.”

Comprehensive health care reform is not possible without system-wide adoption of health information technology, which improves the quality of healthcare delivery, increases patient safety, decreases medical errors, and strengthens the interaction between patients and healthcare providers.

With Meaningful Use now providing the way forward, eligible providers across the country increasingly understand the benefits for themselves and their patients, and are adopting Meaningful Use compliant electronic health records.

Initiated in 2006 by the Healthcare Information and Management Systems Society (HIMSS), National Health IT Week has emerged as a landmark occasion for using health IT as part of the overall solution to improve America’s healthcare as a bipartisan, federally led, market driven initiative.

The Week consists of events across the country, including National Health IT Weekparticipants —vendors, provider organizations, payers, pharmaceutical/biotech companies, government agencies, industry/professional associations, research foundations, and consumer protection groups— all working together to elevate national attention to the advantages of advancing health IT.

View our full list of partners and updates on the Week’s events. Working together with our growing coalition of stakeholders, IHIF is helping to transform healthcare for all.

IHIF Announces Legislators of the Year

May 16, 2016

Recognizes those making significant policy impact on the state’s health science sector

Contact: Kristin Jones, President and CEO
Indiana Health Industry Forum
kjones@ihif.org or 317-686-0994

INDIANAPOLIS, IN (May 16, 2016) — In conjunction with its 2016 Annual Meeting, the Indiana Health Industry Forum (IHIF) recognized U.S. Representative Larry Bucshon, M.D., and State Senator Patricia Miller as the IHIF 2016 Legislators of the Year.  “Each year we recognize federal and state legislators who have demonstrated a commitment to excellence in public health policy and service to Indiana’s health science business community”, said Kristin Jones, President and CEO of IHIF.  “This year we are so pleased to be able to recognize both Representative Bucshon for his work and leadership on the Congressional 21st Century Cures Initiative and Senator Miller for her dedication to health issues and 30 years of public service”.

 

Prior to being elected to Congress, Representative Bucshon spent his career specializing in cardiothoracic surgery and has performed hundreds of heart surgeries.  As one of only a few practicing physicians in Congress his experience with all aspects of health care delivery afford him unique insight and perspective on efforts to improve patient care and seek value across the health care spectrum.  He has been an educated voice of opposition to a proposed CMS rule that would implement a new Medicare Part B drug payment model that would negatively affect patient access to essential medication and treatment therapies.   He has also been a leader in the fight against opioid abuse, working with Representative Paul Tonko (D-NY) to introduce, “The Opioid Use Disorder Treatment Expansion and Modernization Act”.

 

Senator Patricia Miller announced earlier this year that she would be retiring from the state legislature after more than 30 years.  Her outstanding efforts as Chair of the Senate Committee on Health and Provider Services have led to policies that have touched and improved the lives of countless Hoosiers. Her commitment to common sense care and high regard for patient dignity are well reflected in her legislative record.

 

“We are proud that Indiana has been so involved, informed, and well represented”, said Jones “and we are pleased to be able to recognize the contributions of Rep. Bucshon and Senator Miller”.   Previous recipients of IHIF’s Legislative Award include: State Representative. Ed Clere (2014), State Senator Brandt Hershman (2014), and U.S. Representative Susan W. Brooks (IN-5) (2015).

Rep. Larry Bucshon Official Photo
U.S. Rep. Larry Bucshon, M.D. (IN-8th)
Member of the House Energy &
Commerce Committee

PatMiller_2013

Senator Patricia Miller (District 32)
Assistant President Pro-Tempore

About IHIF

The Indiana Health Industry Forum (IHIF) is a statewide trade association representing members of Indiana’s health science business community.  The diverse members of IHIF generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information and to become a member, please visit www.ihif.org

 

###

 

BIO Releases First-Ever Industry Principles on Value of Biopharmaceuticals

February 5, 2016

BIO Logo Horizontal RGB

News Release

1201 Maryland Avenue, SW l Ste. 900

Washington, D.C. l 20024 l 202-962-9200

Web: www.bio.org

Blog: www.biotech-now.org

Twitter: @IAmBiotech

For Immediate Release

Contact:Daniel Seaton
202-470-5207

BIO Releases First-Ever Industry Principles on Value of Biopharmaceuticals

Innovative biopharmaceutical industry focused on value, advocating for needed reforms

Washington, D.C. (February 3, 2016) – The Biotechnology Innovation Organization (BIO) today released new Principles on the Value of Biopharmaceuticals. These voluntary Principles represent the first-ever systemic, industry-endorsed set of commitments by research-based biopharmaceutical companies to support comprehensive and sustainable solutions to improve patient access to and affordability of innovative medicines that are transforming how we treat and cure patients with once-devastating diseases.

The following statement may be attributed to BIO President and CEO Jim Greenwood:

“America’s innovative biopharmaceutical companies exist to advance the health and well-being of patients by tackling head-on the unrelenting scientific challenges inherent in the discovery, development and delivery of new, high-value cures and treatments. These Principles represent a commitment by our industry to do our part to improve the ability of patients to access those medicines on a sustainable and affordable basis, while also continuing to take the big risks and make the enormous investments required to fulfill the promise of the next generation of cures.”

Among other principles, BIO members are committed to open dialogue with patients, healthcare providers, and payers on the value of their biopharmaceutical innovations and to take these stakeholders’ views into account in the development and delivery of such cures and treatments.  In addition, BIO and its members will work with such stakeholders, as well as policymakers, to explore a broad range of novel delivery approaches to maximize the value of these innovations for patients and the overall healthcare system, including by seeking to remove legal barriers that currently limit the ability to engage in value-based contracting and communications.

“As evidenced by these Principles, the research-based biopharmaceutical industry welcomes the vigorous public debate about the cost and value of our medical innovations,” Greenwood said.  “BIO members already are doing their part to find sustainable patient-centered solutions, and as an industry we are committed to doing even more.  To effectively accomplish these goals, it is essential that other stakeholders in the healthcare system do their part, as well. To that end, we call upon payers, healthcare providers and policymakers to join with us in designing and implementing comprehensive solutions that will ensure patients continue to benefit from the tremendous medical advances biotechnology has made possible.”

The full Principles on the Value of Biopharmaceuticals are available here. To learn more about the value of innovation, please visit here.

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

IHIF 2016 Legislative Breakfast and Industry Briefing

January 18, 2016

 

An IHIF Signature Event

Presented by:

 Print     HWFH new logo     IMDMC 2013 Logo

You are Invited!

January 27, 2016

 

Downtown Indianapolis Hilton Hotel

120 W. Market Street

Monument Hall (Lower Level)

 

With Featured Speakers

Lt. Governor Sue Ellspermann

and

Rep. Ed Clere, House Public Health Committee

Due to a schedule change, Senator Pat Miller will be unable to join us for the program.  We are pleased to announce that Lt. Governor Sue Ellsperman will be with us to share her thoughts on the direction of the life science industry in Indiana.  Rep. Ed Clere will provide an assessment of the 2016 Legislative Session with special regard for public health matters.

Registration 7:15 am

Program 7:30 – 8:30 am

Welcome and Introduction

Kristin Jones, IHIF

  IMDMC Legislative Update

Kathy Heuer, Executive Director

“The Value of Medicines”

Saiza Elayda, PhRMA

The Indiana Health Industry Forum is a state-based trade association for members of Indiana’s health and life science manufacturing community.  The goal of the annual legislative breakfast briefing is to educate and engage IHIF members on Federal and State public policy issues and activities.  The event is open to member companies of IHIF, the Indiana Medical Device Manufacturers Council (IMDMC), the Hoosiers Work for Health/PhRMA task force, and all members of the Indiana General Assembly.  There is no charge to attend but please register.  For more information on IHIF, please visit www.ihif.org

 

Please register here to attend the breakfast briefing

Industry Groups Partner on MedTech/Life Sciences Policy Forum for State Legislators

September 21, 2015

FOR IMMEDIATE RELEASE                                      CONTACTS:       Kathy Heuer, IMDMC (260) 609-2802

Aug. 31, 2015                                                                                                    Kristin Jones, IHIF (317) 686-0994

 

Lt. Governor and Sen. Hershman Lead Forum to kick off new Life Sciences Policy Series
Industry leaders join state legislators to discuss evolving life sciences ecosystem in Indiana

 

The Indiana Medical Device Manufacturers Council and the Indiana Health Industry Forum today introduced The MedTech/Life Sciences Policy Forum to State Legislators. The new Policy Forum was introduced at an event held at Roche Diagnostics in Indianapolis and featured two panel discussions led by Lt. Governor Sue Ellspermann and Senator Brandt Hershman. Legislators also were given a hard-hat tour of Roche’s new Learning & Development Center, which is under construction on its north-eastside campus.

 

Panelists contributing to the discussions were Teresa Lubbers, Indiana Commission for Higher Education; Steve Braun, Commissioner at the Indiana Dept. of Workforce Development; Brad Bishop, Ex. Dir. at Orthoworx in Warsaw; David Broecker, Indiana Biosciences Research Institute; Kevin Brinegar, Indiana Chamber of Commerce; Tom Ryder, President/CEO of Genesis Plastics Welding; and Jennifer Zinn and Greta Clark, both from Roche Diagnostics.

 

The MedTech/Life Sciences Policy Forum is a series designed for members of the General Assembly that will focus on Indiana’s strengths in the sector and policy recommendations to help spawn a dynamic life sciences ecosystem in the state. Both the Medical Device and Life Science Industries along with the Health Industry in Indiana have interests in the retention, growth and attraction of current and new businesses in their sectors.

 

The next Forum will be held in New Albany on September 24, at the Purdue Technology Center.

 

The Forum will also hold meetings during session to discuss legislation that may be presented during the legislative session at the Statehouse that affects the Medical Device and Life Sciences Industries.

 

###

 

About IMDMC

The Indiana Medical Device Manufacturers Council (IMDMC) serves to represent the interests of its member companies in the delivery of innovative, life-changing technologies to patients. IMDMC advocates on behalf of its members and is dedicated to providing ongoing training and education to help equip its members to adapt to the changing environment in which they operate. Through the relationships it develops, its recognized expertise and its passionate advocacy, IMDMC serves to increase public awareness of the economic and health benefits the Indiana Medical Device Industry delivers throughout the world. For more information please visit www.imdmc.org

 

About IHIF

The Indiana Health Industry Forum (IHIF) is a statewide trade association representing members of Indiana’s health science business community.  The diverse members of IHIF generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information and to become a member, please visit www.ihif.org